Fluoro-L-Thymidine

PreclinicalSmall molecule

AAssistance Publique - Hôpitaux de Paris

Fluoro-L-Thymidine is one of 29 small molecule programs targeting Chemoradiotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemoradiotherapyTerminated

ChemoradiotherapyPreclinical

Terminated

Competition

Competitive Landscape

33 competitors in Chemoradiotherapy

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

5 2

Eloxatin

Teva

Phase 3

4 3

Taxol

Teva

Phase 3

2 4

Imjudo

AstraZeneca

Phase 3

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

10 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 7

Paraplatin

AAvyxa

Phase 3

3 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 10

Alimta

SShawn Eagle

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00236275·60 enrolled

Chemoradiotherapy1 trial

Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET

Terminated·—·N/A·NCT01065818·6 enrolled

Bevacizumab1 trial

Molecular Imaging With Erlotinib and Bevacizumab

Completed·UUniversity of Cologne·Phase 2·NCT01047059·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fluoro-L-Thymidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluoro-L-Thymidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluoro-L-Thymidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Fluoro-L-Thymidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Chemoradiotherapy1 trial

Bevacizumab1 trial

References

Drug Info

Quick Facts

Related News